Related Experiment Videos
Evolution of bone marrow transplantation--the original immunotherapy
J D Campbell1, G Cook, T L Holyoake
1Academic Transfusion Medicine Unit (ATMU), Dept of Medicine, Royal Infirmary, 10 Alexandra Parade, G31 2ER., Glasgow, UK.
Trends in Immunology
|April 5, 2001
Summary
Allogeneic bone marrow transplantation (BMT) offers a cure for chronic myeloid leukaemia (CML). New targeted therapies may replace BMT, offering hope to patients lacking a donor.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Allogeneic bone marrow transplantation (BMT) is a curative option for chronic myeloid leukemia (CML).
- Approximately 60% of CML patients lack a suitable donor for BMT.
- Signal transduction inhibitors targeting the bcr-abl oncogene represent a new therapeutic avenue.
Purpose of the Study:
- To discuss novel therapeutic strategies for chronic myeloid leukemia.
- To explore the potential of combining drug and immune-based approaches for CML treatment.
- To provide hope for CML patients ineligible for BMT.
Main Methods:
- Review of current BMT procedures for CML.
- Analysis of signal transduction inhibitors targeting the bcr-abl oncogene.
- Discussion of potential synergistic effects of combined drug and immune therapies.
Main Results:
- BMT has been a successful treatment for CML for decades.
- Targeted therapies show promise in treating CML, potentially reducing reliance on BMT.
- Combined drug and immune-based strategies could enhance CML treatment efficacy.
Conclusions:
- New targeted drugs may offer an alternative to BMT for CML patients.
- Combining novel drugs with immune-based approaches could improve outcomes for CML.
- These advancements offer hope for a broader patient population, including those without suitable donors.